Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations by Cossins, J et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.unizh.ch
Year: 2006
Diverse molecular mechanisms involved in AChR deficiency
due to rapsyn mutations
Cossins, J; Burke, G; Maxwell, S; Spearman, H; Man, S; Kuks, J; Vincent, A; Palace,
J; Fuhrer, C; Beeson, D
Cossins, J; Burke, G; Maxwell, S; Spearman, H; Man, S; Kuks, J; Vincent, A; Palace, J; Fuhrer, C; Beeson, D.
Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations. Brain 2006,
129(10):2773-2783.
Postprint available at:
http://www.zora.unizh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.unizh.ch
Originally published at:
Brain 2006, 129(10):2773-2783
Cossins, J; Burke, G; Maxwell, S; Spearman, H; Man, S; Kuks, J; Vincent, A; Palace, J; Fuhrer, C; Beeson, D.
Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutations. Brain 2006,
129(10):2773-2783.
Postprint available at:
http://www.zora.unizh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.unizh.ch
Originally published at:
Brain 2006, 129(10):2773-2783
Diverse molecular mechanisms involved in AChR deficiency
due to rapsyn mutations
Abstract
Congenital myasthenic syndromes are inherited disorders of neuromuscular transmission characterized
by fatigable muscle weakness. Autosomal recessive acetylcholine receptor (AChR) deficiency
syndromes, in which levels of this receptor at the neuromuscular junction are severely reduced, may be
caused by mutations within genes encoding the AChR or the AChR-clustering protein, rapsyn. Most
patients have mutations within the rapsyn coding region and are either homozygous for N88K or
heteroallelic for N88K and a second mutation. In some cases the second allele carries a null mutation
but in many the mutations are missense, and are located in different functional domains. Little is known
about the functional effects of these mutations, but we hypothesize that they would have an effect on
AChR clustering by a variety of mechanisms that might correlate with disease severity. Here we
expressed RAPSN mutations A25V, N88K, R91L, L361R and K373del in TE671 cells and in rapsyn-/-
myotubes to determine their pathogenic mechanisms. The A25Vmutation impaired colocalization of
rapsyn with AChR and prevented agrin-induced AChR clusters in rapsyn-/- myotubes. In TE671 cells,
R91L reduced the ability of rapsyn to self-associate, and K373del-rapsyn was significantly less stable
than wild-type. The effects of mutations L361R and N88K were more subtle: in TE671 cells, in
comparison with wild-type rapsyn, L361R-rapsyn showed reduced expression/stability, and both
N88K-rapsyn and L361R-rapsyn showed significantly reduced co-localization with AChR.
N88K-rapsyn and L361R-rapsyn could effectively mediate agrin-induced AChR clusters, but these were
reduced in number and were less stable than with wild-type rapsyn. The disease severity of patients
harbouring the compound allelic mutations was greater than that of patients with homozygous rapsyn
mutation N88K, suggesting that the second mutant allele may largely determine severity.
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Summary 
Congenital myasthenic syndromes are inherited disorders of neuromuscular transmission characterised by 
fatigable muscle weakness.  Autosomal recessive AChR deficiency syndromes, in which levels of AChR at 
the neuromuscular junction are severely reduced, may be caused by mutations within genes encoding the 
AChR or the AChR-clustering protein, rapsyn.  Most patients have mutations within the rapsyn coding region 
and are either homozygous for N88K or heteroallelic for N88K and a second mutation.  In some cases the 
second allele carries a null mutation but in many the mutations are missense, and are located in different 
functional domains.  Little is known about the functional effects of these mutations, but we hypothesise that 
they would have an effect on AChR clustering by a variety of mechanisms that might correlate with disease 
severity.   
Here we expressed RAPSN mutations A25V, N88K, R91L, L361R, and K373del in TE671 cells and in 
rapsyn -/- myotubes to determine their pathogenic mechanisms.  The A25Vmutation impaired colocalisation 
of rapsyn with AChR and prevented agrin-induced AChR clusters in rapsyn -/- myotubes.  In TE671 cells, 
R91L reduced the ability of rapsyn-EGFP to self-associate, and K373del-rapsyn-EGFP was significantly less 
stable than wild type. The effects of mutations L361R and N88K were more subtle: in TE671 cells, in 
comparison to wild type rapsyn, L361R-rapsyn showed reduced expression/stability, and both N88K-rapsyn 
and L361R-rapsyn showed significantly reduced co-localisation with AChR.  N88K-rapsyn and L361R-
rapsyn could effectively mediate agrin-induced AChR clusters, but these were reduced in number and were 
less stable than with wild type rapsyn. The disease severity of patients harbouring these mutations was found 
to reflect the disruption of rapsyn function suggesting that the second mutant allele (in addition to N88K) 
may play a role in determining disease severity.   
 
Keywords:  Congenital myasthenic syndrome, rapsyn, acetylcholine receptor, neuromuscular junction. 
Abbreviations 
AChR = acetylcholine receptor; α-BuTx = α-bungarotoxin; MuSK = muscle-specific tyrosine kinase; PBS = 
phosphate buffered saline; BSA = bovine serum albumin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
  Synaptic transmission plays a pivotal role in controlling the passage of information through the 
nervous system. Synaptogenesis involves the juxtaposition of pre- and postsynaptic structures and the 
generation of regions of densely packed neurotransmitter receptors. At the neuromuscular junction (NMJ) a 
core pathway involving agrin, muscle-specific tyrosine kinase (MuSK), acetylcholine receptors (AChRs) and 
the AChR-clustering protein rapsyn is thought to be responsible for maintaining synaptic structure and for the 
aggregation and localisation of AChR on the postsynaptic folds (Sanes and Lichtman, 2001).  Although 
mutations underlying congenital myasthenic syndromes (Engel and Sine, 2005) have been identified in post-
synaptically-expressed genes encoding MuSK (Chevessier et al., 2004) and the voltage gated sodium 
channel, Nav1.4 (Tsujino et al., 2003), the majority are located in the AChR or rapsyn genes (a list of  these 
mutations is given in Ohno and Engel, 2004).  AChR mutations have been well studied, but the functional 
effects of rapsyn genes have not yet been characterised in detail. 
      In early developmental stages the AChR is expressed throughout muscle, with clusters or ‘hot-spots’ 
of AChR forming independently of the nerve in the process of muscle prepatterning (Kummer et al., 2005). 
Motoneuron axons then extend into the muscle and release agrin, which activates MuSK through an as yet 
undetermined mechanism.  AChRs are phosphorylated and their expression becomes restricted to the synaptic 
and perisynaptic regions of the muscle. As the junction matures, dense, stable clusters of AChR become 
localised at the crests of the post-synaptic folds of the NMJ.  Rapsyn interacts directly with AChRs and is 
essential for agrin-induced clustering of the AChR (Fuhrer et al., 1999; Gautam et al., 1995).  In rapsyn -/- 
mice AChR clusters fail to form, the postsynaptic folds do not form properly, nerve sprouting occurs and the 
mice die at birth without functional synapses (Gautam et al., 1999; Gautam et al., 1995). AChRs, in turn, are 
required for synaptic clustering of rapsyn, revealing an intimate functional interdependence of AChRs and 
rapsyn (Marangi et al., 2001; Ono et al., 2004).  
 The effect of deletions and truncations of rapsyn on its function in vitro have led to the proposal of 
four functional domains:  rapsyn is attached to the juxtaneural postsynaptic membrane by a myristylation 
moiety; seven tetratricopeptide repeat (TPR) domains are thought to mediate rapsyn self-association (Eckler 
et al., 2005; Ramarao et al., 2001); a zinc finger/coiled-coil domain has been implicated in interaction of 
rapsyn with the AChR (Bezakova and Bloch, 1998; Ramarao et al., 2001); and a RING-H2 domain is thought 
to be involved in rapsyn binding to scaffolding proteins such as dystroglycan (Bartoli et al., 2001).    
           Mutations within the RAPSN gene have been shown to underlie a high proportion of AChR 
deficiency syndromes (Burke et al., 2003; Dunne and Maselli, 2003; Ioos et al., 2004; Maselli et al., 2003; 
Muller et al., 2003; Ohno et al., 2002; Ohno et al., 2003) which can occur early in life or during adulthood.  
The disease is recessive, and in most cases patients are either homozygous for N88K or heteroallelic for 
N88K and a second mutation.  The severity of disease is variable, ranging from little functional impairment 
to the patient requiring assisted ventilation.  In particular, the disorder in childhood is frequently 
characterised by severe apnoeic attacks. To date the precise mechanisms by which these different RAPSN 
mutations lead to AChR deficiency have not been thoroughly studied. 
           Here we investigated the functional effects of five RAPSN gene mutations, including N88K, and 
asked whether these correlated with the clinical phenotype.  Our data show that diverse molecular 
mechanisms disrupt rapsyn function, and that the major effect of N88K-rapsyn is to reduce the stability of 
AChR-clusters.  However, in compound heterozygotes of N88K and a second mutation, the second mutant 
allele is likely to play a role in determining disease severity.   
 
 
 
 
Materials and Methods 
Patients with AChR deficiency and the identification of RAPSN mutations 
  Patients and DNA samples were recruited through the congenital myasthenia service in Oxford, UK.  
All were negative for antibodies against the AChR.  Information was from family interviews, case note 
review and clinical examination obtained by an assessor blinded to the results of the genetic functional 
analysis. Assessment was complimented by the myasthenia activities of daily living scoring system (MG-
ADL); an eight-question survey of symptom severity, with each response graded from 0 (normal) to 3 (most 
severe) (Wolfe et al., 1999).  Mutations were identified by direct sequencing of PCR amplicons containing 
the eight RAPSN exons and their flanking non-coding regions and confirmed by restriction endonuclease 
digestion as described previously (Burke et al., 2004).  Approval for this study was obtained from the Central 
Oxford Research Ethics Committee 
 
Plasmids and constructs 
  pBabe-PURO-sn was a kind gift from Dr Chris Norbury, Cancer Research UK, WIMM, Oxford.  
pEGFP-N1 was purchased from Clontech.  Restriction enzymes were purchased from New England Biolabs. 
Human rapsyn cDNA minus the stop codon was amplified using primers 5’-
TGCGAAGCTTGCCACCATGGGGCAGGACCAGACCAAG and 5’-
TCGTGGATCCCGTACAAAGCCAGGCTTCATGGA and was cloned into pEGFP-N1 using HindIII and 
BamHI restriction sites, such that EGFP and rapsyn were in the same reading frame.  Mutagenesis was 
carried out using the QuikChange mutagenesis kit purchased from Stratagene.  The primers that were used 
for mutagenesis were 5’-CCAGTCCAACCAGACAGAGAAGGTATTGCAGGTGTGGACAAAGG and 
5’-CCTTTGTCCACACCTGCAATACCTTCTCTGTCTGGTTGGACTGG for A25V; 
5’-CCTCCTGGAGAGCTACCTGAAACTGGCACGCAGCAACGAGAAGC and 
5’-GCTTCTCGTTGCTGCGTGCCAGTTTCAGGTAGCTCTCCAGGAGG for N88K; 
5’-GGGAGCTACCTGAACCTGGCACTC AGCAACGAGAAGCTGTGCG and 
5’-GCGAGACGTTCTCGTTGCTGAGTGCCAGGTTCAGGTAGC TCTCC for R91L; 
5’-CGGCGAGTCCATAGGCGAGAACAGCCGGCTGCAGGCCC and 
5’-GGGCCTGCAGCCGGCTGTTCTCGCCTATGGACTCGCCG for Kdel373 and 5’-
GCGTGGAGGAGACGGAGCGTTACTGCGGCCTGTGCGGC and 
5’-GCCGCACAGGCCGCAGTAACGCTCCGTCTCCTCCACGC for L361R.  Mutations were confirmed 
by DNA sequencing.  EGFP-tagged rapsyn and mutants were excised from pEGFP-N1 using HindIII (filled) 
and NotI, and were cloned into XhoI (filled) and NotI digested pBabe-PURO-sn. 
 
Cell lines 
  TE671, COS-7 and C2C12 cells were purchased from ATCC and GP + E86 (Markowitz et al., 1988) 
retroviral-producing cell line was a kind gift from Professor Roy Bicknell, Cancer Research UK, WIMM 
Oxford.  TE671, COS-7 and GP + E86 cell lines were maintained at 37°C in DMEM (Sigma-Aldrich) 
supplemented with 10% FCS (TCS Cellworks Ltd) and 100 units/ml each of penicillin G and streptomycin 
(PS) purchased from Invitrogen.  C2C12 cells were maintained at 37°C in DMEM supplemented with 20% 
FCS and PS, and were fused in DMEM containing 2% FCS and PS.  Rapsyn -/- (clone 11-7) myoblasts 
(Fuhrer et al., 1999) were maintained at 33°C with 5%CO2 on plates coated with matrigel matrix (BD 
Biosciences Discovery Labware, San Hose, CA, USA).  Growth media was DMEM supplemented with 0.5% 
chick embryo extract (United States Biological, MA, USA), 4 units/ml mouse recombinant interferon-γ 
(Sigma-Aldrich), 20% FCS and PS.  To induce fusion, myoblasts were moved to 37°C with 5% CO2, and the 
media was replaced with fusion media (DMEM containing 10% horse serum (Sigma-Aldrich) and PS).  
Fusion media was replaced every day until myotubes formed. 
 Transfections 
TE671 cells were seeded at 2 x 105 cells per well in 6 well-plates and the following day were transfected with 
a total of 3μg DNA per well using calcium phosphate precipitation.  Amounts of DNA used per well was 1μg 
AChR α-subunit DNA, 0.5 μg each of AChR β-, δ- and ε-subunit cDNA and 0.5μg of rapsyn cDNAs or 
pcDNA3.1-hygro for ‘no rapsyn’ control transfections.  Transfections with only rapsyn and no AChR were 
carried out using 3 μg/well of rapsyn expression plasmids.  GP + E86 cells were transfected with the pBabe-
PURO-rapsyn constructs using Fugene (Roche Diagnostics), using 2.5μg DNA and 7.5μl Fugene in a 25cm2 
flask.  Three days following transfection cells were selected using 8μg/ml puromycin (Sigma-Aldrich), and 
two weeks later were cell-sorted to obtain the top 5% fluorescent cells.   
 
Retroviral production and infection 
  For retroviral production transfected GP + E86 cells were incubated for three days in the minimal 
volume of growth media without puromycin.  The media was harvested and centrifuged to remove cell 
debris, aliquoted and snap frozen on dry ice.  Retrovirus was stored at -80°C.  Retrovirus was used neat and 
was incubated with myoblasts overnight at 33°C after which the media was replaced with growth media.  
Puromycin was added three days after infection.   
 
Fluorescence/confocal microscopy 
  Microscopy was performed on an Axion 200 inverted Zeiss fluorescence microscope, an Olympus 
BX60 wide field fluorescence microscope or on a BioRad Radiance 2000 confocal microscope.  AChR on TE 
cells was detected by incubation for 1 hour at room temperature with the B3 MAb, which binds the 
extracellular domain of the AChR β subunit (Jacobson et al., 1999), diluted 1:500 in DMEM containing 
20mM Hepes and 1%BSA, before being washed three times with PBS.  Cells were fixed with 3% 
paraformaldeyde at room for 20mins, washed three times with PBS and incubated with secondary antibody 
Alexa Fluor® 594 goat anti-mouse IgG (H+L) diluted 1:1000 in PBS containing 1% BSA (Molecular 
Probes).  Cells were washed 3 x in PBS and mounted in fluorescent mounting media (Dako Cytomation).  
AChR on myotubes were labelled at 37°C with tetramethylrhodamine α-bungarotoxin (Molecular Probes) 
diluted 1:1000 in fusion media.  Cells were washed 3 x in fusion media, fixed in fusion media containing 3% 
formaldehyde for 20mins at room temp., washed 1x in PBS and mounted in fluorescent mounting media.  
Images were captured by using Openlab software (Improvision) or LaserSharp 2000 software (BioRad).  
 
Western blots 
  TE671 cells were removed from 6-well plates using trypsin/EDTA in PBS, centrifuged and the 
pellets were resuspended in 5x protein loading buffer.  The cell extract was incubated at 95°C for 1 hour and 
then subjected to SDS PAGE using Novex precast 4-20% NuPage gels.  Protein was transferred to 
nitrocellulose and rapsyn was detected using anti-rapsyn MAb 1234 (Abcam) followed by anti-mouse-HRP 
and ECL (Amersham).  α-tubulin was detected on the same Western blots using a MAb (Sigma-Aldrich) 
followed by anti-mouse-HRP and ECL. 
 
Production of agrin and generation of AChR clusters on myotubes 
  To generate soluble rat agrin, COS cells were transiently transfected with construct s-agrin-(4,19), 
kindly given by Werner Hoch (Hopf and Hoch, 1997), using PEI.  On the following day the media was 
replaced with fresh media.  Conditioned media was harvested two days later, aliquoted and snap frozen.  
AChR clustering activity of the agrin was titrated by incubation overnight with C2C12 myotubes.  Clusters 
were labelled at 37°C for 1 hour with tetramethylrhodamine α-bungarotoxin (Molecular Probes) diluted 
1:1000 in fusion media and washed three times with fusion media.  Cells were fixed with 3% 
paraformaldehyde and cluster number and length was counted using an Axion 200 inverted Zeiss 
fluorescence microscope.  AChR clustering on rapsyn -/- myotubes was carried out by incubation overnight 
at 37°C with the optimal dilution of agrin in fusion media.  Labelling of clusters was as described for C2C12 
cells.  
 
Analysis of colocalisation and clustering 
  16 bit-depth images from a radiance 2000 confocal microscope were analysed blinded using 
MetaMorph, Universal Imaging Corporation.  Colocalisation of rapsyn with AChR was quantitated as percent 
of green pixels colocalising with red pixels, and conversely colocalisation of AChR with rapsyn was 
quantitated as percent of red pixels colocalising with green pixels.  Densitometry of rapsyn and AChR and 
area of clusters was also analysed using MetaMorph. 
 
Results 
Patients 
  Eighteen different mutations within or affecting the RAPSN coding region (Fig 1) were identified in 
patients with CMS associated with AChR deficiency.  We chose five of these mutations, A25V, N88K, 
R91L, L361R, and K373del for functional studies to determine the underlying basis for the endplate AChR 
deficiency.  These included four missense mutations and one single amino acid deletion within rapsyn.   The 
patients with these mutations are described in Table 1 and include two pairs of siblings, patients 4 and 5, and 
12 and 14.  The age at onset varied from birth (ten patients) to later childhood (one patient) or adult life.  In 
affected individuals each of these mutations was found to be heteroallelic with mutation N88K or 
homozygous for N88K.   
 Four of nine homozygous for N88K had arthrogryposis multiplex congenita (AMC) but congenital 
joint contractures were also evident in two other patients with compound heteroallelic mutations  (not 
significant).  Six of the patients with symptoms from birth had at least one exacerbation during childhood that 
required hospital admission, often with assisted ventilation during thee attacks. Apnoea attacks occurred in all 
three patients with the rapsyn mutation K373del, and in patient 6 (rapsyn mutations L361R and N88K) but 
only in 2/9 rapsyn patients homozygous for N88K (not significant).  Patient 1 (rapsyn mutations A25V and 
N88K) and the siblings with rapsyn mutations K373del and N88K had older brothers with a similar 
phenotype to them, but who had died in infancy from respiratory failure. 
 All but patient 1 has been examined, usually on treatment, within the last two years. At his last 
examination, patient 1 (rapsyn mutations A25V and N88K) had some mild weakness of his neck and upper 
limbs and mild bulbar and ocular symptoms.  Patient 2 (rapsyn mutations R91L and N88K) continues to have 
severe weakness despite treatment with pyridostigmine.  Patient 3 (rapsyn mutations K373del and N88K) has 
mild limb weakness but significant bulbar difficulties on neostigmine. She also requires assisted ventilation at 
night for nocturnal hypoventilation. Patients 4 and 5 have mild weakness on examination but moderate 
impairment of activities of daily living, and require treatment with both pyridostigmine and 3,4-
diaminopyridine. Patient 6 (rapsyn mutations L361R and N88K) and the patients homozygous for N88K have 
little or no weakness with pyridostigmine treatment, and this is generally reflected in their low MG-ADL 
scores (Table 1) which differ significantly between those homozygrous for N88K and those with compound 
heteroallelic mutations (Mann Whitney p=0.029). 
 
Functional analysis of RAPSN mutations 
  To examine whether the clinical phenotype reflected the functional effects of the mutations on 
AChR clustering, cDNA encoding human rapsyn  (Buckel et al., 1996) was cloned into mammalian 
expression vector pcDNA3.1 or given a C-terminal EGFP tag using pEGFP-N1.  Preliminary experiments 
showed that inclusion of the C-terminal EGFP tag did not affect rapsyn-induced clustering of the AChR in 
the TE671 muscle cell line (data not shown). Subsequently respective mutations A25V, N88K, R91L, L361R 
and K373del were introduced into the rapsyn-EGFP expression plasmid for the functional studies.  
 
R91L inhibits rapsyn self-clustering 
  We first studied the effect of the mutations on rapsyn self-association, which is a critical process in 
the clustering of the AChR.  To do this, plasmids constructed to express wild type or mutant rapsyn-EGFP 
were transfected into TE671 cells, images were captured on a confocal microscope (Fig. 2A-F) and the 
percent of fluorescent cells that contained clusters was counted.  Western blots showed that the diffuse 
cellular EGFP signal was not due to protein degradation or GFP clipping (data not shown). R91L-rapsyn 
showed a significant reduction in self-association, with only 45% of fluorescent cells containing clusters 
compared with 75% for wild type (Fig 2G; repeated measures ANOVA, p=0.006, with post-test for rapsyn 
R91L, p<0.05).  Even those cells that did contain clusters with R91L-rapsyn had very few large clusters per 
cell that were probably non-specific aggregates  (Fig 2D). By contrast, self-clustering in all the other rapsyn 
constructs was similar to the wild type.  Since rapsyn self-association is crucial for AChR clustering, it is 
likely that this is the pathogenic mechanism for this mutation.  
 
Mutation K373del reduces the stability of rapsyn 
  We next analysed the expression levels of the remaining four rapsyn mutants by western blotting.  
Wild type or mutant rapsyn-EGFP was transfected on day 0 (with or without the AChR subunits) into TE671 
cells, and a time course for levels of rapsyn and  α-tubulin (control) was carried out.  An example of TE671 
cells transfected with rapsyn alone is shown in Fig 3A, and similar results were obtained when cells were co-
transfected with AChR (data not shown).  Densitometry was performed to obtain a ratio of rapsyn: α-tubulin 
and the results were normalized to levels of wild type-rapsyn-EGFP (Fig 3B).  K373del-rapsyn-EGFP 
expression drastically decreased to only approximately 10% that of wild type rapsyn by day 4 and was 
undetectable by day 5.  This initial robust expression of K373del followed by rapid loss strongly suggests that 
deletion of K373 reduces the stability of rapsyn to a much greater extent than the other mutations.  The same 
results were obtained with a second set of DNA preparations.  A25V and L361R also reduced rapsyn levels 
to around 30% but interestingly N88K had no effect on rapsyn expression. 
 Immunocytometric analysis of the co-transfected TE671 cells confirmed the results from western 
blot analysis and also showed that cell surface expression of AChR was unaffected by the rapsyn mutations 
studied here (data not shown).  The dramatic effect of K373del on rapsyn stability is likely to be the major 
molecular mechanism underlying rapsyn dysfunction for this mutation.   
 
A25V-rapsyn does not associate with the AChR and abrogates AChR clustering 
  Next we investigated the effect of the remaining three mutations, A25V, N88K and L361R on the 
interactions between rapsyn and AChR by looking at colocalisation of the two proteins.  First, in a blinded 
experiment, TE671 cells were co-transfected with wild type or mutant rapsyn-EGFP constructs and the 
AChR cDNAs.  Two days following transfection the AChR was immunolabelled and the cells were fixed and 
mounted.  Photographs were taken using a confocal microscope and colocalisation of rapsyn with AChR (% 
of green pixels that are also red) and AChR with rapsyn (% of red pixels that are also green) was analysed 
using MetaMorph.  Figs 4A-D show examples of confocal images of the green fluorescent rapsyn constructs, 
AChR labelled with MAb B3 fluorescing red, and merged images.  Wild type rapsyn-EGFP showed the best 
colocalisation with 62% colocalising with the AChR and 52% of AChR colocalising with rapsyn-EGFP (Fig 
4E).  A25V-Rapsyn-EGFP showed the least colocalisation, with only 10% of rapsyn colocalising with the 
AChR and 17% of AChR colocalising with rapsyn (Fig 4E).  A25V-rapsyn did not localise at the cell surface;  
rather A25V-rapsyn-GFP clusters were bigger and appeared intracellularly, in the middle of the cell soma. 
The AChR signal at the cell surface, in the A25V-rapsyn-EGFP/AChR co-transfections, showed minimal 
clustering (Fig 4B) as would be expected in the absence of functional rapsyn.  Rapsyn harbouring mutations 
N88K and L361R showed approximately a 50% reduction in levels of colocalisation of both rapsyn with 
AChR and AChR with rapsyn compared with wild type in TE671 cells (Fig 4E), 
        To further understand the effect of this rapsyn mutation on co-localisation we studied agrin-induced 
AChR clusters.  Wild type- or A25V-rapsyn-EGFP were introduced into mouse rapsyn -/- myoblasts using 
retroviruses, myoblasts were fused and incubated with agrin overnight, and AChR clusters were visualised 
using α-BuTx-TRITC.  Many clusters were induced as expected in myotubes expressing wild type-rapsyn-
EGFP (Fig 5A), but clusters in A25V-rapsyn-EGFP myotubes were virtually undetectable (Fig 5B) whereas 
they were present with N88K and L361R (Fig 5C,D).  The number of clusters longer than 3μm was counted 
in each field.  The A25V mutation reduced the number of clusters by 97.5% compared with that of wild type-
rapsyn-EGFP (Fig 5E).  As expected, no clusters were observed in agrin-treated rapsyn -/- myotubes (data not 
shown).      
       Confocal images showed that the AChR was located along the cell surface of myotubes.  In merged 
confocal images of agrin-treated myotubes expressing A25V-rapsyn-EGFP, the AChR appeared as red lines 
along the edge of the myotubes whereas A25V-rapsyn-EGFP was green inside the myotubes, indicating that 
rapsyn was not located at the cell surface and did not colocalise with the AChR (Fig5G), confirming the 
results shown in TE671 cells (Fig. 4B).  By contrast, in merged images of myotubes expressing wild type-
rapsyn-EGFP, in addition to the presence of clusters, the edges of the myotubes were yellow indicating that 
rapsyn reached the cell surface and colocalised precisely with un-clustered AChR (Fig 5F).    
 
  
N88K- and L361R-rapsyn-EGFP form agrin-induced clusters that are unstable. 
  Despite the reduction in colocalisation of N88K- and L361R-rapsyn-EGFP with AChR in TE671 
cells (Fig 4E), they were still able to effectively mediate agrin-induced AChR clusters in rapsyn -/-myotubes 
(Figs 5C and D).  However, the number of AChR clusters was reduced by 30% for N88K and by as much as 
60% for L361R (Fig 5E).  The clusters that did form were similar to those formed by wild type-rapsyn-EGFP 
with respect to average area, density of rapsyn-EGFP, density of AChR and colocalisation of rapsyn with 
AChR (data not shown).   
 The reduction in number of clusters could be due to less efficient cluster formation or to clusters 
being unstable once formed.  To test this myotubes were incubated overnight with agrin, washed three times 
to remove the agrin, and incubated in differentiation media for five hours prior to labelling with α-BuTx-
TRITC (Fig 6A-F).  Over the five hour incubation period the number of AChR clusters per field with wild 
type-rapsyn-EGFP decreased by only 10% (Fig 6G), indicating that the clusters are relatively stable.  By 
contrast, with N88K- or L361R-rapsyn-EGFP the AChR clusters were disassembled as reflected by the 85% 
reduction in the number of clusters per field (Fig 6G).   
     
Discussion 
  We studied four missense mutations and one single amino acid deletion within rapsyn that are 
present in patients with congenital myasthenia due to endplate AChR deficiency.  They were found to disrupt 
rapsyn function via different intracellular molecular mechanisms.  R91L abrogates rapsyn self clustering, 
K373del leads to the rapid rapsyn degradation, and A25V annuls the association of rapsyn and AChR.  The 
pathogenic mechanisms of N88K and L361R appear to be more subtle.  Mutation L361R reduces the level of 
rapsyn either through lower expression or increased turnover.  Both L361R and N88K affect the association 
of rapsyn with AChR, reduce the number of agrin-induced AChR clusters in rapsyn -/- myotubes and 
dramatically reduce the stability of AChR clusters.  A summary of the results is shown in Table 2.    
Tetratricopeptide repeat domains mediate protein-protein interaction (Blatch and Lassle, 1999).  Rapsyn has a 
central region made up of multiple TPR domains, and deletion mapping identified TPR1 and TPR2 (domains 
as shown in Fig 1) as the most important for rapsyn self clustering.  In addition deletion mutants of these 
domains were found to have a dominant negative effect on rapsyn self clustering when co-expressed with 
wild type rapsyn (Eckler et al., 2005).  R91L, located in TPR2, was the only one of the mutations we 
analysed that clearly affected rapsyn self association.  This single missense substitution dramatically inhibited 
rapsyn-rapsyn oligomerisation, which, theoretically, should still be able to occur via any of the other six TPR 
domains.  By contrast with the deletion experiments (Eckler et al 2005), we did not obviously detect a 
dominant negative effect of R91L-rapsyn when co-expressed with wild type rapsyn-DsRed2 (data not 
shown), moreover in patients reviewed at the Oxford Myasthenia Clinic we have not identified a pedigree 
with rapsyn mutations in which there is a dominant inheritance pattern.  However, the possibility of dominant 
rapsyn mutations should not be ruled out. 
        Deletion of lysine at position 373 reduces the levels of rapsyn in vitro.  The mechanism for AChR 
deficiency could be due to the reduced levels of functional rapsyn in cells, or alternatively intrinsic rapsyn 
instability in vivo may lead to reduced stability of AChR clusters.  In addition reporter gene assays indicate 
that mutations in the RAPSN promoter may cause congenital myasthenic syndromes through reduced 
expression of rapsyn mRNA (Ohno et al., 2003), and consequently reduced rapsyn expression.  The 
association of rapsyn with AChR leads to metabolic stabilisation of AChR in the postsynaptic membrane 
(Wang et al., 1999) and an increased ratio of rapsyn to AChR is thought to enhance  AChR stability 
(Gervasio and Phillips, 2005; Losen et al., 2005).  It is not clear whether reduced rapsyn expression causes 
AChR deficiency through an effect on the clustering process itself or through instability of formed or 
partially formed clusters. 
      The A25V-rapsyn mutation has a profound effect on AChR clustering.  In TE671 cells and rapsyn -/- 
myotubes, the mutant rapsyn was not present at the membrane and rarely colocalised with the AChR.  When 
A25V-rapsyn-EGFP was expressed in rapsyn -/- myotubes agrin-induced clustering was almost completely 
abrogated.  Another rapsyn mutation close to the N-terminus, L14P, previously reported (Ohno et al., 2002) 
gave a similar expression pattern (data not shown).  A possible explanation for the action of these mutations 
is an effect on myristylation and thereby binding to the plasma membrane.  Alternatively the rapsyn N-
terminal region may be crucial for trafficking to the cell surface, or L14P and A25V may disrupt rapsyn-
AChR interactions.  However, previous reports have postulated that the coiled-coil domain (residues 298-
331) is the major region responsible for these interactions (Bezakova and Bloch, 1998; Ramarao et al., 2001).   
   Studies of mutations N88K and L361R suggest they affect several aspects of rapsyn function.  Both 
N88K-rapsyn and L361R-rapsyn showed similar functional characteristics in our expression systems, 
although lower levels of L361R-rapsyn were observed following transfection into TE671 cells due either to 
reduced L361R-rapsyn expression or stability.  In TE671 cells both mutations led to an approximate 50% 
reduction in rapsyn colocalisation with AChR, and both formed reduced numbers of large aggregates of 
clusters.  A decrease in colocalisation of N88K-rapsyn-EGFP and AChR in HEK 293 cells was previously 
observed (Ohno et al., 2002).  In agrin-induced AChR clusters in rapsyn -/- myotubes the number of clusters, 
compared to wild type, was decreased by approximately 30% (N88K) or 60% (L361L).  However, when 
agrin was withdrawn, a dramatic decrease in the number of clusters compared with wild type was observed, 
indicating that clusters incorporating these two mutations are unstable.   
  A significant association with truncating mutations in the second allele and arthrogryposis has been 
noted (Beeson et al., 2005) suggesting that the lack of function of the second allele may influence disease se 
phenotype. Many factors, including age and the fluctuating course of the disorder make it very difficult to 
obtain an objective measure of disease severity.  We applied the myasthenia gravis activities of daily living 
(MG-ADL) score to children as well as adults as a simple symptom-based questionnaire as a means of 
assessing disability when the patient is in a stable phase (Table 1).  In our cases we found significantly higher 
MG-ADL scores in the patients with the functionally more disruptive mutations A25V, R91L and K373del (p 
= 0.024, Mann Whitney), even when including N88K homozygous patients 11 and 12 where MG-ADL 
scores were likely to be increased by co-morbid conditions (patient 11 also has Perthe’s disease and both 
patients 11 and 12 had a body mass index of approximately 40).   
           Other anecdotal evidence suggesting an involvement of the second mutation with disease severity is 
that we have not identified deaths in siblings in kinships where the affected child is homozygous for N88K; 
none of the patients homozygous for N88K have required 3,4-diaminopyridine in addition to their 
anticholinesterase treatment, implying either that their disease may be less severe or that they respond better 
to anticholinesterase medication; and 4 out 5 of our late onset cases of AChR deficiency due to rapsyn 
mutations are homozygous for N88K. 
        We dissected the pathogenic mechanisms of five naturally occurring rapsyn mutations.  The data 
supports the hypothesis that dysfunction in the second mutation of a heteroallelic N88K-rapsyn patient 
contributes to disease severity.  It is tempting to speculate that the underlying cause of the fever-induced 
severe apnoeic attacks associated with rapsyn mutations is increased N88K-rapsyn-AChR-cluster instability. 
A raised body temperature might lead to an increase in both protein metabolism and membrane fluidity, thus 
compromising the structural integrity of the already unstable AChR clusters.  Moreover, the similarity in 
functional characteristics of N88K-rapsyn and L361-rapsyn revealed in this study suggests that there are 
likely to be patients with AChR deficiency that are either homozygous or heteroallelic for non-N88K 
mutations within the RAPSN coding region. 
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Table 1                                             Patient data 
Pt. 
No 
Age of onset / 
sex / current 
age (yr) 
AMC Assisted 
ventilation 
Apnoeas Treatment MG-ADL 
(/24) 
Mutation 
1  Birth / M / 55 - + - P ND A25V, N88K 
2 10 / M / 17 - - - P 7 R91L, N88K 
3 Birth / F / 1 + + + N 10 K373del, N88K 
4 Birth / M / 11 - - + P+D 5 K373del, N88K 
5 Birth / M / 13 - + + P+D 5 K373del, N88K 
6 Birth / F / 10 + + + P 4 L361R, N88K 
7 Birth / F / 4 + + - P 4 N88K, N88K 
8 Birth / M / 7 + - + P 2 N88K, N88K 
9 Birth / F / 23 + + - P 1 N88K, N88K 
10 Birth / M / 26 + - + P 2 N88K, N88K 
11 Birth / M / 30 - - - P 6 N88K, N88K 
12 26 / F / 52 - - - P 6 N88K, N88K 
13 48 / M / 53 - - - P 1 N88K, N88K 
14 21 / M / 54 - - - P 0 N88K, N88K 
15 41 / F / 76 - - - P 0 N88K, N88K 
 
Pt. No, patient number; yr, years; M, male; F, female; AMC, arthrogryposis multiplex 
congenita; MG-ADL, myasthenia gravis activities of daily living score; ND not done; P, 
pyridostigmine; N, neostigmine; D, 3,4-diaminopyridine. 
Table 2                                                         Summary of Results  
Mutation
Rapsyn cluster 
formation in 
TE671 cells
Rapsyn stability
Colocalisation
with AChR
Agrin-induced 
AChR clusters 
(no. per field)
Agrin-induced 
clusters after 
washing
Primary defect
WT Good Good >50% 13 Seen Normal
A25V Good Reduced 10% <1 nd Poor rapsyn–AChR
interaction
N88K Good Good 25% 9 Severely 
reduced
Unstable AChR
clusters
R91L Reduced nd nd nd nd Poor rapsyn self-
association
L361R Good Reduced 30% 7 Severely 
reduced
Unstable AChR
clusters
K373del Good Severely reduced nd nd nd Instability of rapsyn
Figure Legends 
Fig. 1.  Schematic diagram of rapsyn protein showing mutations that have been 
identified in congenital myasthenic patients.  The functional domains of rapsyn are also 
shown.   
 
Fig. 2.  Mutation R91L abrogates clustering of rapsyn in TE671 cells.  A-F  Confocal 
images showing WT and mutant rapsyn-EGFP in TE671 cells two days following 
transfection.  Rapsyn R91L (B) had reduced self-clustering, but the other mutants (C-F) 
were similar to WT (A).  Magnification 60x.  Bar = 10μm  G  Quantitation of rapsyn 
clustering using wide field fluorescence microscopy.  Number of green fluorescent cells 
containing rapsyn clusters was expressed as a percentage of total number of green 
fluorescent cells in 40 fields.  Results are the average two experiments.   
 
Fig. 3.  K373del reduces the stability of rapsyn.  A.  WT and mutant rapsyn-EGFP were 
transfected into TE671 cells and analysed by western blotting.  Rapsyn was detected by 
MAb clone 1234 and α-tubulin was labelled as a control.  B.  The ratio of rapsyn: α-
tubulin was obtained by carrying out densitometry using LabWorks.  Expression of 
Kdel373-rapsyn-EGFP decreased rapidly compared with wild type rapsyn, indicating 
that it is unstable.  A25V and L361R were also unstable but to a lesser degree, and 
N88K-rapsyn-EGFP was as stable as wild type rapsyn.   
 
Fig. 4.  Mutation A25V reduces colocalisation of rapsyn with the AChR.  TE671 cells 
were co-transfected with WT-, A25V-, N88K- or L361R-rapsyn-EGFP and the AChR 
subunits.  AChR was detected using MAb B3 and images were taken using a confocal 
microscope.  A.  Confocal images showing rapsyn (green), AChR (red) and merged 
images (yellow where rapsyn and AChR colocalise) in TE671 cells, 2 days following 
transfection.  WT-, N88K- and L361R-rapsyn-EGFP all show good colocalisation (A, C, 
D).  Very little colocalisation of rapsyn and AChR is observed with A25V-rapsyn-EGFP 
(B) and AChR is only minimally clustered but is evenly distributed on the cell surface.  
Magnification 60x.  Bar = 10μm. E. MetaMorph was used to calculate colocalisation of 
rapsyn with AChR (% green pixels that are red) and AChR with rapsyn (% red pixels 
that are green).   
 
Fig. 5. A25V-rapsyn-EGFP does not form agrin-induced clusters in rapsyn -/- myotubes.  
Myotubes expressing WT-, A25V-, N88K- or L361R-rapsyn-EGFP were treated with rat 
soluble agrin overnight and AChR was labelled with BuTx-TRITC. Images of 40 fields 
per construct were taken using a wide-field inverted fluorescence microscope, and 
example images of AChR clusters are shown (A-D).  Magnification 32x.  Bar = 40μm.  
The number of clusters longer than 3μm were counted and the average number of 
clusters per field was calculated (E).  Mutant A25V inhibits the formation of AChR 
clusters.  Confocal images of rapsyn -/- myotubes expressing A25V-rapsyn-EGFP (F) or 
WT- rapsyn-EGFP (G) indicate that A25V-rapsyn-EGFP does not reach the cell surface.  
Magnification 60x.  Bar = 10μμ. 
 
Fig. 6.  Agrin-induced AChR clusters that form with N88K- or L361R-rapsyn-EGFP 
are unstable.  Rapsyn -/- myotubes expressing WT-rapsyn-EGFP (A,B), N88K- 
rapsyn-EGFP (C,D) or L361R-rapsyn-EGFP (E,F) were treated with agrin overnight 
and then either labelled with α-BuTx-TRITC (A, C and E) or washed for 5 hours to 
remove the agrin prior to labelling (B, D and F).  Myotubes were visualised and the 
number of clusters in 40 fields were counted and expressed as average number of 
clusters/field (G).  Magnification 40x, bar = 20μm.     
 
Membrane 
association
Rapsyn self-association AChR
binding
L14P
N88K 553ins5
L361R
R91L
46insC
123insG
Q124X
A25V
1177del2
K373del
L169P
V165M
E147K IVS3+1GJA
N-Myr
TPR1 TPR2 TPR3 TPR6 TPR7TPR4 TPR5
Coiled 
coil
RING H2
Figure 1
L283P
β-dystroglycan
binding
C97X
1136delins9
WT
L361R
Fig 2
K373del
A
R91L
A25V
N88K
D
E
F
B
C
WT A25V N88K R91L L361R K373del
0
25
50
75
100
%
 
g
r
e
e
n
 
c
e
l
l
s
 
t
h
a
t
 
c
o
n
t
a
i
n
 
c
l
u
s
t
e
r
s
Figure 2 G
Figure 3
A WT A25V N88K L361R K373del
rapsyn
α-tubulin
ra
tio
 o
f r
ap
sy
n:
a-
tu
bu
lin
w
ith
 e
ac
h 
m
ut
at
io
n 
ex
pr
es
se
d 
as
 a
 p
er
ce
nt
 o
f W
T 
-10
10
30
50
70
90
110
130
1 4 5 6
Day
WT
A25V
N88K
L361R
K373del
B
L361R
N88K
Fig 4
WT
Rapsyn AChR Merge
A
B
D
C
A25V
Figure 4E
0
10
20
30
40
50
60
70
WT A25V N88K L361R
P
e
r
c
e
n
t
 
c
o
l
o
c
a
l
i
s
a
t
i
o
n
rapsyn colocalised with
AChR
AChR colocalised with
rapsyn
WT
N88K
L361R
A25V
A
B
D
C
Fig 5
Rapsyn construct
N
u
m
b
e
r
 
o
f
 
c
l
u
s
t
e
r
s
 
p
e
r
 
f
i
e
l
d
Figure 5E
WT A25V N88K L361R
0
5
10
15
WT 
A25V
Fig 5 F
G
WT
N88K
A
C D
EL361R F
B
AGRIN AGRIN
5 HOUR WASH
Fig 6
Nu
m
b
e
r
 
o
f
 
c
l
u
s
t
e
r
s
 
p
e
r
 
f
i
e
l
d
WT          WT N88K        N88K L361R      L361R
washed washed washed
0
5
10
15
Figure 6G
